Veeda Oncology announced the acquisition of U.S based International Oncology Network (ION) Clinical Research today. In addition, Veeda Oncology and ION agreed to a 5 year exclusive agreement under which Veeda Oncology will provide clinical research support to the ION Network of sites. The acquisition of ION Clinical Research would provide Veeda with immediate access to the 50 ION sites that conduct oncology clinical research in the US.

Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.

Commenting on the acquisition, Binoy Gardi, Co-Group Managing Director and Co-Founder, Veeda Group said “the agreement with ION substantially increases our ability to provide our sponsors with rapid global accrual of oncology patients beyond our relationships with institutions in India, Eastern Europe, Western Europe as well as our current site relationships in the US.”

Matt Bowman, President and CEO of Veeda Oncology stated “the access to the 50 ION Clinical Research sites significantly compliments our strategy of rapid access to oncology patients for global clinical trials. In addition, all of the personnel of ION Clinical Research will be joining Veeda Oncology and we are very pleased to be adding such terrific oncology professionals”.

Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research (Veeda CR), which is a full service global CRO specializing in the early clinical development of drugs with top class clinical pharmacology units in the UK, Europe and India. Veeda CR has dedicated clinical pathology, bioanalysis, biomarker and immunogenicity laboratory services which are GLP accredited and has assess to an extensive database of volunteers.